Case study
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
External resource. Not made or verified by Public Protocol.
FDA announcement of 8 December 2023 approving Casgevy, its first approved CRISPR/Cas9 therapy, and Lyfgenia for sickle cell disease in patients 12 and older.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease
- Maintainer
- US Food and Drug Administration
- Licence, as stated at its source
- Not stated on the page opened
- Open or commercial
- Commercial
- Maturity
- WorkingOur reading, 16 November 2026
- Safety
- S3medical
- Review
- Listed 16 November 2026by Public Protocol editors
- Checked
- 16 November 2026
- Next check due
- 16 May 2027
- Steward
- Public Protocol editors
Where it sits in the blueprint
- Domains
- Stages
Learn
- Elements it supports
- Context
Climate, setting, scale, cost and skill: not stated in this entry. Check the source against your own place and numbers.
Verification
No verification is recorded on Public Platform for this entry. Records are added when someone reads it for accuracy, reviews it with a stated qualification, builds it or measures it.
Record
- How it came in
Seed catalogue, 16 November 2026. Listed from Praecise open research. The source was opened and described on the date shown.
- Licence
Not stated on the page opened. Read at https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease. How licences are recorded
- Something wrong?